Drug Trial Radar · NCT01046825
Mature B-Cell Lymphoma And Leukemia Study III
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
128
Actual
Start
Sep 9, 2010
Primary completion
Aug 31, 2023
Study completion Aug 2027
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.
Conditions
- Mature B-Cell Lymphoma
Interventions
COPADDrug
Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
COP, COPD M3, CYMDrug
GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
COP, COPADM8, CYVEDrug
Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3. COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin. COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF. Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF. Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications. Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications. In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gene Differential Expression Profiling of Burkitt Lymphoma (BL) vs. Non-BL in the US and Other Selected Geographic Regions of the WorldTime frame: 1 year after the participant is enrolled
- Catalog and Estimate Frequencies of Copy Number Variations in Childhood LymphomasTime frame: 1 year after the participant is enrolled
- Integrated Analysis of CNVs and Gene Expressions in the US and Other Selected Geographic Regions of the WorldTime frame: 1 year after the participant is enrolled
- Pattern and Frequency of XLP Gene Mutations Presenting With B-cell Lymphomas in the United States and Selected Geographic RegionsTime frame: 1 year after the participant enrollment
- Frequency of EBV Protein Expression (e.g., EBNA 3) in EBV-positive LymphomasTime frame: 1 year after the participant is enrolled
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Rady Children's Hospital San Diego
San Diego, California
St. Jude Children's Research Hospital
Memphis, Tennessee
Children's Cancer Hospital
Cairo, Egypt
National University Health System
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.